The clonoSEQ test can detect and monitor MRD in patients with certain types of blood cancer
MedGenome has announced that it is offering Adaptive Biotechnologies’ next-generation sequencing (NGS)-based clonoSEQ Assay to assess Minimal Residual Disease (MRD) in patients with Multiple Myeloma (MM), Chronic Lymphocytic Leukemia (CLL), and B-cell Acute Lymphoblastic Leukemia (B-ALL).
The clonoSEQ test can detect and monitor MRD in patients with certain types of blood cancer. It helps to detect MRD even at low levels offering a prognostic value to clinicians, helping them to assess how patients respond to treatment or if any change in disease management is required.
The test determines MRD at very low levels (10-6 sensitivity). The test identifies dominant immune cell clones at the time of high disease burden that can be monitored after the treatment to determine MRD.
- Advertisement -